Eli Lilly, Amylin and Alkermes, partners on the first-ever once-a-week drug for diabetes, announced that patients saw their blood sugar go down by two percent and their weight drop an average nine-and-a-half pounds after one year on the experimental treatment.
Amylin fell more than 8% Monday after data from an important diabetes meeting sparked concern about competition to the drug Byetta. How to trade?
Gary Anderson thinks investors should look beyond America's borders for their stock-market winnings.
We are covering the ADA meeting today and tomorrow because most of the major data came out over the weekend or is coming out later today. Or so we thought.
"You continue--day after day--to knock the company at every opportunity. I understand you had a difficult relationship with the CEO before, but you shouldn't hold a grudge against the company for it..."
Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.
The American Society of Clinical Oncology annual meeting, which starts today in Chicago, couldn't get any bigger for ImClone Systems and its Erbitux partners Bristol-Myers Squibb and the German Merck (no relation to the U.S.-based Merck).
With the ASCO conference beginning Friday new cancer drugs are likely to grab headlines. How should you trade ahead of biotech’s biggest weekend?
My recent post on the new Evista commercial from Eli Lilly elicited a few opinions including one from a woman who says she participated in a focus group for the spot. Laura Bliss says her comments at the time were that the "togas...made the women look like they were already sick....
A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.
Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.
So, I admit I watched a lot of television last night and saw a commercial for a relatively new osteoporosis-breast cancer prevention combo drug from Eli Lilly called Evista. Actually, I saw it three times.
A fight has erupted in Congress over the question of whether drug makers and other companies should be allowed to keep patents they obtained by misrepresentation or cheating, The New York Times reports.
The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"
Merck and Eli Lilly reported earnings today, and CNBC asked the pharmaceutical companies’ chief executives and an analyst to discuss the results and the sector as a whole.
Stocks close mixed as quarterly results from Bank of America and National City fueled worries about bank earnings, while energy and tech gained.